Obesity Treatment Market by Treatment Type (Pharmacotherapy, Surgical Procedures), Drug Class (Appetite Suppressants, GLP-1 Receptor Agonists, Lipase Inhibitors), Route of Administration, Patient Age Group, Distribution Channel, End-User - Global Forecast
Description
The Obesity Treatment Market was valued at USD 15.46 billion in 2024 and is projected to grow to USD 16.69 billion in 2025, with a CAGR of 8.39%, reaching USD 29.46 billion by 2032.
A compelling introduction to how clinical breakthroughs, payer dynamics, patient pathways, and commercial models are transforming obesity care delivery
The trajectory of obesity treatment systems is evolving rapidly as clinical innovation intersects with changing patient expectations, payer scrutiny, and novel commercial models. This introduction frames the current environment by emphasizing the interplay between emerging pharmacotherapies, procedural advances, and shifting care pathways that together reshape how patients interact with the healthcare ecosystem. Rather than treating these developments as isolated changes, it is critical to view them as mutually reinforcing forces that alter clinical decision-making, referral dynamics, and the economic calculus of providers and payers.
Moreover, contemporary treatment journeys highlight increased patient agency, a stronger focus on long-term disease management, and greater attention to comorbidities that complicate both clinical practice and reimbursement. Consequently, stakeholders must appreciate that adoption curves are governed not only by clinical efficacy but also by accessibility, administration convenience, and the ability of health systems to integrate multidisciplinary care. This perspective sets the stage for deeper analysis, where technological innovation, regulatory adjustments, and commercial strategy converge to present both challenges and tangible opportunities for improving outcomes across diverse patient populations.
Mapping the transformative shifts across innovation, regulatory change, patient expectations, and commercial incentives that are redefining obesity care
The landscape of obesity treatment is being reshaped by several transformative shifts that extend beyond drug launches and procedural enhancements. Technological advances in pharmacotherapy and device design are accompanied by an evolving regulatory environment that is becoming more adaptive to chronic disease management paradigms. As a result, clinical trial design, endpoints, and post-approval evidence commitments are converging toward longer-term, outcomes-focused measures that matter to clinicians and payers alike.
At the same time, patient expectations are changing: individuals increasingly prioritize treatments that integrate with daily life, minimize adverse effects, and align with broader wellness goals. Payers are responding by refining coverage frameworks and emphasizing value-based arrangements that link reimbursement to demonstrable clinical and economic outcomes. Commercial incentives are adapting as well, with cross-sector collaborations and innovative distribution strategies emerging to accelerate access. Taken together, these shifts are redefining the criteria for commercial success, requiring manufacturers, providers, and payers to synchronize clinical evidence generation with pragmatic delivery models and targeted stakeholder engagement.
Assessing the cumulative implications of United States tariff policy changes on cross-border supply chains, pricing, manufacturing incentives and access
Tariff policy changes in the United States have a cascading effect across the obesity treatment value chain, influencing raw material sourcing, manufacturing footprint decisions, and end-to-end logistics. In 2025, the cumulative impact of adjusted tariffs has amplified the cost sensitivity of imported active pharmaceutical ingredients, specialized device components, and ancillary supplies. Consequently, manufacturers are reassessing supplier contracts and considering regionalization of production to mitigate the exposure to cross-border duties. This reorientation has implications for lead times, inventory strategies, and the capital allocation decisions that underwrite production scale and flexibility.
Beyond manufacturing, tariffs affect pricing strategies and negotiations with distributors and payers. Heightened import costs can compress margins or, alternatively, prompt price adjustments that risk limiting patient access if reimbursement systems do not adapt. In response, some organizations are accelerating investments in domestic manufacturing, diversifying supplier bases, and redesigning product formulations where feasible to reduce reliance on tariff-sensitive inputs. Regulators and policymakers also play a role: trade measures can spur policy dialogues about strategic sourcing for essential therapies and the importance of supply chain resilience. In sum, tariff dynamics are not a simple cost input; they shape strategic choices across sourcing, regulatory engagement, and commercial modeling that will determine how quickly new treatments can be produced, priced, and distributed at scale.
Illuminating segmentation opportunities across treatment modalities, drug classes, administration routes, age cohorts, distribution channels and end-users
Segmentation analysis reveals differentiated drivers of demand, clinical adoption, and commercial opportunity that vary by modality, mechanism, route of administration, patient demographics, distribution strategy, and care setting. Treatments categorized by type show clear contrasts between pharmacotherapy and surgical procedures, where pharmacotherapy subdivides into over-the-counter options and prescription medications and surgical procedures encompass bariatric surgery, gastric bypass, and laparoscopic techniques. Each subcategory presents distinct clinician workflows, monitoring requirements, and patient counseling needs, which in turn influence how stakeholders prioritize investment and outreach.
When examining drug classes, the landscape ranges from appetite suppressants to GLP-1 receptor agonists, lipase inhibitors, and metabolism boosters, each with unique efficacy and safety profiles that affect prescriber confidence and payer scrutiny. Route of administration, whether oral or parenteral, further determines adherence patterns, site-of-care economics, and the necessity for specialized delivery infrastructure. Patient age groups, spanning adults, elderly, and pediatric populations, demand tailored safety, dosing, and support considerations that influence clinical trial design and post-market services. Distribution channels, from offline retail to online retail, play a pivotal role in reach and patient convenience, while end-user settings such as hospitals and clinics, specialty clinics, and weight loss and wellness centers dictate patient throughput, multidisciplinary coordination, and reimbursement pathways. Integrating these segmentation dimensions provides a nuanced view of where clinical differentiation, commercial focus, and implementation support will yield the greatest returns.
Regional dynamics and comparative opportunities across the Americas, EMEA, and Asia-Pacific shaping access, adoption, and care models for obesity treatments
Regional dynamics shape how treatments are developed, reimbursed, and delivered, with meaningful contrasts across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets that inform strategic prioritization. In the Americas, health systems and payer frameworks frequently emphasize real-world evidence and cost-effectiveness, which drives demand for robust outcomes data and scalable distribution approaches that can accommodate large, diverse populations. This environment favors solutions that demonstrate durable benefits and align with value-based contracting models.
Europe, Middle East & Africa present a mosaic of regulatory and reimbursement landscapes where centralized guidelines often coexist with country-level heterogeneity, creating both barriers and opportunities for targeted launches. Here, stakeholders must navigate complex HTA processes and localized clinical expectations while leveraging regional centers of excellence to build momentum. In Asia-Pacific, growth is propelled by rising awareness, expanding private sector capacity, and a strong appetite for novel interventions, yet adoption is tempered by differences in clinical practice patterns and affordability constraints. Across all regions, local regulatory engagement, culturally attuned patient support programs, and tailored distribution strategies are essential components of successful rollouts and sustainable access.
Strategic behaviors, partnership models, and value chain moves by biopharma, device makers, and service providers that are reshaping obesity care
Companies operating in this space are adopting a range of strategic playbooks to capture clinical and commercial value, with emphasis on agile partnerships, evidence generation, and patient support infrastructure. Many organizations are shifting from single-product promotional models toward integrated offerings that combine pharmacological efficacy with adherence services, digital tools, and provider education to improve outcomes in real-world settings. Collaboration with specialty clinics and weight loss and wellness centers is increasingly important to establish referral networks and multidisciplinary care pathways that support long-term disease management.
Moreover, strategic alliances between pharmaceutical developers and device manufacturers or service providers are enabling bundled solutions that can address both clinical and logistical barriers to adoption. Firms that prioritize transparent outcomes reporting, invest in post-marketing surveillance, and engage proactively with payers to demonstrate value are better positioned to secure favorable formularies and coverage terms. At the same time, companies that maintain manufacturing flexibility and diversified distribution capabilities can more readily respond to supply chain shocks and regional regulatory variability, reinforcing commercial resilience while preserving patient access.
Clear, prioritized actions for industry executives, payers, clinicians, and innovators to accelerate access, optimize care pathways and sustain value creation
Industry leaders should pursue a focused set of actions to align clinical promise with commercial realities and patient needs. First, prioritize evidence generation that demonstrates meaningful, durable outcomes in real-world settings and design payer-centric studies that address both clinical endpoints and downstream cost offsets. Second, invest in integrated patient support ecosystems that combine education, adherence tools, and coordination between specialty clinics and primary care to optimize persistence and outcomes.
Third, diversify supply chains and explore regional manufacturing or contract development partnerships to reduce exposure to tariff-driven cost volatility and logistics disruptions. Fourth, tailor go-to-market strategies by segment and region, ensuring that distribution channel approaches-whether offline retail, online retail, or direct-to-clinic-match patient behavior and provider workflows. Lastly, engage early with payers and health systems to negotiate outcome-linked arrangements and to co-design pathways that facilitate adoption while protecting access. Collectively, these actions create a pragmatic roadmap for translating scientific progress into sustainable clinical and commercial impact.
A rigorous mixed-methods approach combining primary interviews, expert validation, literature synthesis, and quantitative cross-checks to ensure data integrity
The research underpinning this analysis employs a rigorous mixed-methods approach to ensure validity, triangulation, and practical relevance. Primary research includes structured interviews with clinicians across care settings, payer representatives, supply chain experts, and pharmacy leaders; these conversations are paired with expert validation panels to test thematic findings and to surface actionable implications. Secondary research synthesizes peer-reviewed literature, regulatory guidance, and grey literature to contextualize trends in clinical efficacy, safety, and care delivery.
Quantitative cross-checks include benchmarking of adoption indicators and breadth-of-evidence assessments, while qualitative coding techniques ensure that recurring themes are systematically identified and prioritized. Throughout the process, quality controls such as data provenance tracking, respondent verification, and iterative stakeholder reviews are applied to reduce bias and to strengthen confidence in conclusions. This methodology balances depth of insight with reproducibility, enabling stakeholders to rely on the report for strategic decision-making and operational planning.
Synthesizing strategic imperatives to guide stakeholders toward sustainable, patient-centric innovations and resilient obesity care ecosystems
The cumulative analysis synthesizes clinical innovation, commercial strategy, regulatory influence, and operational realities into a unified view of how obesity treatment is evolving. Key imperatives emerge around aligning evidence generation with payer and clinician needs, designing patient-centric delivery that accommodates diverse age groups and routes of administration, and building resilient supply chains that can withstand policy and trade fluctuations. These priorities inform where investments in manufacturing, partnerships, and patient engagement will have the most durable effect.
Importantly, the path forward requires coordinated action across stakeholders: manufacturers must pair scientific rigor with pragmatic commercialization tactics; providers should adopt integrated care pathways; and payers need to craft reimbursement frameworks that reward sustained outcomes. By pursuing these aligned approaches, stakeholders can advance treatments that improve patient health while enhancing system-level sustainability and access. The conclusion underscores the necessity of translating insight into targeted initiatives that balance short-term feasibility with long-term innovation.
Please Note: PDF & Excel + Online Access - 1 Year
A compelling introduction to how clinical breakthroughs, payer dynamics, patient pathways, and commercial models are transforming obesity care delivery
The trajectory of obesity treatment systems is evolving rapidly as clinical innovation intersects with changing patient expectations, payer scrutiny, and novel commercial models. This introduction frames the current environment by emphasizing the interplay between emerging pharmacotherapies, procedural advances, and shifting care pathways that together reshape how patients interact with the healthcare ecosystem. Rather than treating these developments as isolated changes, it is critical to view them as mutually reinforcing forces that alter clinical decision-making, referral dynamics, and the economic calculus of providers and payers.
Moreover, contemporary treatment journeys highlight increased patient agency, a stronger focus on long-term disease management, and greater attention to comorbidities that complicate both clinical practice and reimbursement. Consequently, stakeholders must appreciate that adoption curves are governed not only by clinical efficacy but also by accessibility, administration convenience, and the ability of health systems to integrate multidisciplinary care. This perspective sets the stage for deeper analysis, where technological innovation, regulatory adjustments, and commercial strategy converge to present both challenges and tangible opportunities for improving outcomes across diverse patient populations.
Mapping the transformative shifts across innovation, regulatory change, patient expectations, and commercial incentives that are redefining obesity care
The landscape of obesity treatment is being reshaped by several transformative shifts that extend beyond drug launches and procedural enhancements. Technological advances in pharmacotherapy and device design are accompanied by an evolving regulatory environment that is becoming more adaptive to chronic disease management paradigms. As a result, clinical trial design, endpoints, and post-approval evidence commitments are converging toward longer-term, outcomes-focused measures that matter to clinicians and payers alike.
At the same time, patient expectations are changing: individuals increasingly prioritize treatments that integrate with daily life, minimize adverse effects, and align with broader wellness goals. Payers are responding by refining coverage frameworks and emphasizing value-based arrangements that link reimbursement to demonstrable clinical and economic outcomes. Commercial incentives are adapting as well, with cross-sector collaborations and innovative distribution strategies emerging to accelerate access. Taken together, these shifts are redefining the criteria for commercial success, requiring manufacturers, providers, and payers to synchronize clinical evidence generation with pragmatic delivery models and targeted stakeholder engagement.
Assessing the cumulative implications of United States tariff policy changes on cross-border supply chains, pricing, manufacturing incentives and access
Tariff policy changes in the United States have a cascading effect across the obesity treatment value chain, influencing raw material sourcing, manufacturing footprint decisions, and end-to-end logistics. In 2025, the cumulative impact of adjusted tariffs has amplified the cost sensitivity of imported active pharmaceutical ingredients, specialized device components, and ancillary supplies. Consequently, manufacturers are reassessing supplier contracts and considering regionalization of production to mitigate the exposure to cross-border duties. This reorientation has implications for lead times, inventory strategies, and the capital allocation decisions that underwrite production scale and flexibility.
Beyond manufacturing, tariffs affect pricing strategies and negotiations with distributors and payers. Heightened import costs can compress margins or, alternatively, prompt price adjustments that risk limiting patient access if reimbursement systems do not adapt. In response, some organizations are accelerating investments in domestic manufacturing, diversifying supplier bases, and redesigning product formulations where feasible to reduce reliance on tariff-sensitive inputs. Regulators and policymakers also play a role: trade measures can spur policy dialogues about strategic sourcing for essential therapies and the importance of supply chain resilience. In sum, tariff dynamics are not a simple cost input; they shape strategic choices across sourcing, regulatory engagement, and commercial modeling that will determine how quickly new treatments can be produced, priced, and distributed at scale.
Illuminating segmentation opportunities across treatment modalities, drug classes, administration routes, age cohorts, distribution channels and end-users
Segmentation analysis reveals differentiated drivers of demand, clinical adoption, and commercial opportunity that vary by modality, mechanism, route of administration, patient demographics, distribution strategy, and care setting. Treatments categorized by type show clear contrasts between pharmacotherapy and surgical procedures, where pharmacotherapy subdivides into over-the-counter options and prescription medications and surgical procedures encompass bariatric surgery, gastric bypass, and laparoscopic techniques. Each subcategory presents distinct clinician workflows, monitoring requirements, and patient counseling needs, which in turn influence how stakeholders prioritize investment and outreach.
When examining drug classes, the landscape ranges from appetite suppressants to GLP-1 receptor agonists, lipase inhibitors, and metabolism boosters, each with unique efficacy and safety profiles that affect prescriber confidence and payer scrutiny. Route of administration, whether oral or parenteral, further determines adherence patterns, site-of-care economics, and the necessity for specialized delivery infrastructure. Patient age groups, spanning adults, elderly, and pediatric populations, demand tailored safety, dosing, and support considerations that influence clinical trial design and post-market services. Distribution channels, from offline retail to online retail, play a pivotal role in reach and patient convenience, while end-user settings such as hospitals and clinics, specialty clinics, and weight loss and wellness centers dictate patient throughput, multidisciplinary coordination, and reimbursement pathways. Integrating these segmentation dimensions provides a nuanced view of where clinical differentiation, commercial focus, and implementation support will yield the greatest returns.
Regional dynamics and comparative opportunities across the Americas, EMEA, and Asia-Pacific shaping access, adoption, and care models for obesity treatments
Regional dynamics shape how treatments are developed, reimbursed, and delivered, with meaningful contrasts across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets that inform strategic prioritization. In the Americas, health systems and payer frameworks frequently emphasize real-world evidence and cost-effectiveness, which drives demand for robust outcomes data and scalable distribution approaches that can accommodate large, diverse populations. This environment favors solutions that demonstrate durable benefits and align with value-based contracting models.
Europe, Middle East & Africa present a mosaic of regulatory and reimbursement landscapes where centralized guidelines often coexist with country-level heterogeneity, creating both barriers and opportunities for targeted launches. Here, stakeholders must navigate complex HTA processes and localized clinical expectations while leveraging regional centers of excellence to build momentum. In Asia-Pacific, growth is propelled by rising awareness, expanding private sector capacity, and a strong appetite for novel interventions, yet adoption is tempered by differences in clinical practice patterns and affordability constraints. Across all regions, local regulatory engagement, culturally attuned patient support programs, and tailored distribution strategies are essential components of successful rollouts and sustainable access.
Strategic behaviors, partnership models, and value chain moves by biopharma, device makers, and service providers that are reshaping obesity care
Companies operating in this space are adopting a range of strategic playbooks to capture clinical and commercial value, with emphasis on agile partnerships, evidence generation, and patient support infrastructure. Many organizations are shifting from single-product promotional models toward integrated offerings that combine pharmacological efficacy with adherence services, digital tools, and provider education to improve outcomes in real-world settings. Collaboration with specialty clinics and weight loss and wellness centers is increasingly important to establish referral networks and multidisciplinary care pathways that support long-term disease management.
Moreover, strategic alliances between pharmaceutical developers and device manufacturers or service providers are enabling bundled solutions that can address both clinical and logistical barriers to adoption. Firms that prioritize transparent outcomes reporting, invest in post-marketing surveillance, and engage proactively with payers to demonstrate value are better positioned to secure favorable formularies and coverage terms. At the same time, companies that maintain manufacturing flexibility and diversified distribution capabilities can more readily respond to supply chain shocks and regional regulatory variability, reinforcing commercial resilience while preserving patient access.
Clear, prioritized actions for industry executives, payers, clinicians, and innovators to accelerate access, optimize care pathways and sustain value creation
Industry leaders should pursue a focused set of actions to align clinical promise with commercial realities and patient needs. First, prioritize evidence generation that demonstrates meaningful, durable outcomes in real-world settings and design payer-centric studies that address both clinical endpoints and downstream cost offsets. Second, invest in integrated patient support ecosystems that combine education, adherence tools, and coordination between specialty clinics and primary care to optimize persistence and outcomes.
Third, diversify supply chains and explore regional manufacturing or contract development partnerships to reduce exposure to tariff-driven cost volatility and logistics disruptions. Fourth, tailor go-to-market strategies by segment and region, ensuring that distribution channel approaches-whether offline retail, online retail, or direct-to-clinic-match patient behavior and provider workflows. Lastly, engage early with payers and health systems to negotiate outcome-linked arrangements and to co-design pathways that facilitate adoption while protecting access. Collectively, these actions create a pragmatic roadmap for translating scientific progress into sustainable clinical and commercial impact.
A rigorous mixed-methods approach combining primary interviews, expert validation, literature synthesis, and quantitative cross-checks to ensure data integrity
The research underpinning this analysis employs a rigorous mixed-methods approach to ensure validity, triangulation, and practical relevance. Primary research includes structured interviews with clinicians across care settings, payer representatives, supply chain experts, and pharmacy leaders; these conversations are paired with expert validation panels to test thematic findings and to surface actionable implications. Secondary research synthesizes peer-reviewed literature, regulatory guidance, and grey literature to contextualize trends in clinical efficacy, safety, and care delivery.
Quantitative cross-checks include benchmarking of adoption indicators and breadth-of-evidence assessments, while qualitative coding techniques ensure that recurring themes are systematically identified and prioritized. Throughout the process, quality controls such as data provenance tracking, respondent verification, and iterative stakeholder reviews are applied to reduce bias and to strengthen confidence in conclusions. This methodology balances depth of insight with reproducibility, enabling stakeholders to rely on the report for strategic decision-making and operational planning.
Synthesizing strategic imperatives to guide stakeholders toward sustainable, patient-centric innovations and resilient obesity care ecosystems
The cumulative analysis synthesizes clinical innovation, commercial strategy, regulatory influence, and operational realities into a unified view of how obesity treatment is evolving. Key imperatives emerge around aligning evidence generation with payer and clinician needs, designing patient-centric delivery that accommodates diverse age groups and routes of administration, and building resilient supply chains that can withstand policy and trade fluctuations. These priorities inform where investments in manufacturing, partnerships, and patient engagement will have the most durable effect.
Importantly, the path forward requires coordinated action across stakeholders: manufacturers must pair scientific rigor with pragmatic commercialization tactics; providers should adopt integrated care pathways; and payers need to craft reimbursement frameworks that reward sustained outcomes. By pursuing these aligned approaches, stakeholders can advance treatments that improve patient health while enhancing system-level sustainability and access. The conclusion underscores the necessity of translating insight into targeted initiatives that balance short-term feasibility with long-term innovation.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
190 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Widespread integration of GLP-1 receptor agonists into primary care obesity protocols
- 5.2. Emergence of digital therapeutics platforms offering personalized obesity management programs
- 5.3. Increasing use of combination pharmacotherapy targeting multiple metabolic pathways for obesity
- 5.4. Expansion of virtual weight loss coaching integrating AI driven behavioral change support
- 5.5. Rising investment in implantable neurostimulation devices for chronic weight management interventions
- 5.6. Growth of personalized genetic screening to guide targeted obesity therapy selection and dosing
- 5.7. Emerging partnerships between biopharma and tech startups to accelerate obesity treatment innovation pipelines
- 5.8. Expansion of insurer reimbursement models covering telehealth obesity services and remote monitoring solutions
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Obesity Treatment Market, by Treatment Type
- 8.1. Pharmacotherapy
- 8.1.1. Over-The-Counter Drugs
- 8.1.2. Prescription Medications
- 8.2. Surgical Procedures
- 8.2.1. Bariatric Surgery
- 8.2.2. Gastric Bypass
- 8.2.3. Laparoscopic Surgery
- 9. Obesity Treatment Market, by Drug Class
- 9.1. Appetite Suppressants
- 9.2. GLP-1 Receptor Agonists
- 9.3. Lipase Inhibitors
- 9.4. Metabolism Boosters
- 10. Obesity Treatment Market, by Route of Administration
- 10.1. Oral
- 10.2. Parenteral
- 11. Obesity Treatment Market, by Patient Age Group
- 11.1. Adults
- 11.2. Elderly
- 11.3. Pediatric
- 12. Obesity Treatment Market, by Distribution Channel
- 12.1. Offline Retail
- 12.2. Online Retail
- 13. Obesity Treatment Market, by End-User
- 13.1. Hospitals & Clinics
- 13.2. Specialty Clinics
- 13.3. Weight Loss & Wellness Centers
- 14. Obesity Treatment Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Obesity Treatment Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Obesity Treatment Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. AbbVie Inc.
- 17.3.2. Apollo Endosurgery, Inc.
- 17.3.3. AstraZeneca PLC
- 17.3.4. Atkins Nutritionals, Inc.
- 17.3.5. BTL Aesthetics
- 17.3.6. C.H. Boehringer Sohn AG & Ko. KG
- 17.3.7. Eli Lilly and Company
- 17.3.8. F. Hoffmann-La Roche Ltd
- 17.3.9. GlaxoSmithKline plc.
- 17.3.10. Herbalife Ltd.
- 17.3.11. Johnson & Johnson Services, Inc.
- 17.3.12. Kellogg Company
- 17.3.13. Medtronic PLC
- 17.3.14. Merck & Co.
- 17.3.15. Novo Nordisk A/S
- 17.3.16. NutriSystem, Inc.
- 17.3.17. Olympus Corporation
- 17.3.18. Pfizer, Inc.
- 17.3.19. ReShape Lifesciences, Inc.
- 17.3.20. Rhythm Pharmaceuticals, Inc.
- 17.3.21. Sanofi SA
- 17.3.22. Takeda Pharmaceutical Company Limited
- 17.3.23. Viking Therapeutics, Inc.
- 17.3.24. VIVUS LLC
- 17.3.25. Zealand Pharma A/S
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
